Sign in Subscribe

neoadjuvant

A collection of 47 issues

KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer A meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2.

AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy

Skip to content The CRC Digest ◇ RESEARCH AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy A post-hoc analysis of the phase III ARISTOTLE trial found that higher tumor cell density predicted improved survival in locally advanced rectal cancer patients receiving irinotecan-intensified neoadjuvant chemoradiotherapy; researchers developed a free

CRC Research Update — August 03, 2026

Today's colorectal cancer research highlights

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights

CRC Research Update — July 27, 2026

Today's colorectal cancer research highlights

Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy A multicenter study of 452 colorectal cancer patients who received neoadjuvant immunotherapy analyzed the incidence of immune-related adverse events and perioperative outcomes following curative surgery. (Zhonghua Wei Chang Wai Ke Za Zhi)

Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer A multicenter, randomized phase III trial evaluated total neoadjuvant therapy with long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is

Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer A phase Ib study to assess the safety of neoadjuvant trifluridine/tipiracil combined with concurrent radiation in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer) This content

CRC Research Update — July 24, 2026

Today's colorectal cancer research highlights

CRC Research Update — July 19, 2026

Today's colorectal cancer research highlights